MHRA paediatric investigation plan
Skyrizi (RISANKIZUMAB)
MHRA paediatric investigation plan MHRA-101250-PIP01-23-M01 (update) · Modification
Key facts
| PIP number | MHRA-101250-PIP01-23-M01 (update) |
|---|---|
| Product names | Skyrizi |
| Active substances | RISANKIZUMAB |
| Therapeutic areas | Immunology -Rheumatology-Transplantation |
| Conditions | Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis) |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Jun 24, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: